Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humacyte (HUMA) Total Liabilities (2024 - 2025)

Humacyte has reported Total Liabilities over the past 2 years, most recently at $113.3 million for Q4 2025.

  • Quarterly results put Total Liabilities at $113.3 million for Q4 2025, down 40.56% from a year ago — trailing twelve months through Dec 2025 was $113.3 million (down 40.56% YoY), and the annual figure for FY2025 was $113.3 million, down 40.56%.
  • Total Liabilities for Q4 2025 was $113.3 million at Humacyte, up from $96.3 million in the prior quarter.
  • Over the last five years, Total Liabilities for HUMA hit a ceiling of $190.5 million in Q4 2024 and a floor of $96.3 million in Q3 2025.